Werewolf Therapeutics, Inc.
- HOWL
- NASDAQ
- Biotechnology
- Cancer Immunotherapy
- Conditionally Activated Biologics
$1.04
Today +6.12%Quote Oct 19, 2026, 08:00 PM UTC
+7.77%over the last month
Max drawdown −10.9%From 1-month high 0.0%3 months +186.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
39
Founded
2017
Market value
$50.5M
Quote Oct 19
Floor
$1.02
1.8% below price
Resistance
$1.05
0.6% above price
Price vs analyst targets
9 analysts
Lowest target
$1.00Highest target
$12.00
$1.00Highest target
$12.00
- Price $1.04
- Average target $6.50
- Analysts' target range
The price is close to the lowest analyst target. Analysts' average target sits about 525% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about HOWLPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free